Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Hinge Health, Inc. Chief Financial Officer James Budge reported an exempt share withholding tied to equity compensation. On 02/01/2026, 3,036 shares of Class A common stock were disposed of at
All 3,036 shares were relinquished by the officer and cancelled by the company in exchange for the company paying his federal and state tax withholding liabilities. After this transaction, he beneficially owned 434,895 Class A common shares in direct form.
Jane Street Group, LLC and affiliated entities filed an amended Schedule 13G reporting a passive stake in Hinge Health, Inc. They report beneficial ownership of 1,588,611 shares of Class A common stock, representing 4.2% of the class, with shared voting and dispositive power over all reported shares.
The filing states the securities were not acquired and are not held to change or influence control of Hinge Health, indicating a passive investment position rather than an activist role.
The Vanguard Group reports beneficial ownership of 2,605,532 shares of Hinge Health Inc common stock, representing 6.87% of the class as of 12/31/2025.
Vanguard reports no sole voting or dispositive power, with shared voting power over 121,736 shares and shared dispositive power over 2,605,532 shares. The securities are held for Vanguard’s clients, who are entitled to dividends and sale proceeds, and no single other person has an interest over 5% of the class.
Vanguard certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Hinge Health. Vanguard also notes an internal realignment on January 12, 2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
Hinge Health, Inc. investor HANSAINVEST Hanseatische Investment-Limited Co reported beneficial ownership of 2,157,071 ordinary shares, representing 5.69% of the class as of December 31, 2025.
The shares are held for investment funds managed by HANSAINVEST, which under German law has sole voting and dispositive power. The position is certified as acquired and held in the ordinary course of business, not to change or influence control of Hinge Health.
Hinge Health, Inc. CEO, Co-Founder, director and 10% owner reported insider transactions dated 01/05/2026. The reporting person converted 166,665 shares of Class B Common Stock into 166,665 shares of Class A Common Stock at an exercise price of $0, then sold 122,368 Class A shares at a weighted average price of $46.2458 and a further 44,297 Class A shares at a weighted average price of $46.7664.
The sales were made under a Rule 10b5‑1 trading plan adopted on September 11, 2025. Following these transactions, indirect holdings include 35,470 Class A shares held by a spouse, and derivative holdings include 14,376,762 shares of Class B Common Stock and 515,705 Class A shares through a spouse, each Class B share being convertible into one Class A share as described in the company’s charter.
A security holder of HNGE has filed a notice of proposed sale under Rule 144 for 166,665 shares of common stock, with an aggregate market value of $7,593,257.40. The filing lists Morgan Stanley Smith Barney LLC as broker, notes that 37,919,155 shares of this class were outstanding, and indicates an approximate sale date of January 5, 2026 on the NYSE.
The shares were acquired on March 22, 2023 through restricted stock awards from the issuer in the same amount. The document also reports prior Rule 10b5-1 sales for Daniel Perez of 166,670 shares of common stock on December 15, 2025 for gross proceeds of $8,088,311.76. By signing, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s operations.
Hinge Health, Inc. reported an insider equity transaction by its President on a Form 4. On 01/01/2026, the officer disposed of 1,118 shares of Class A common stock at $46.45 per share under transaction code F, which indicates shares withheld to cover taxes on vesting equity awards. After this tax-related share withholding, the reporting person beneficially owned 768,660 shares of Class A common stock, held directly. The filing notes that the shares relinquished were cancelled by the company in exchange for the company’s agreement to satisfy the officer’s federal and state tax withholding obligations arising from the vesting of restricted stock units.
Hinge Health, Inc. reported that its Chief Financial Officer disposed of Class A common stock in a routine tax-related transaction. On 01/01/2026, the CFO had 3,243 shares of Class A common stock withheld and cancelled at a value of $46.45 per share in an exempt transaction coded "F" under Section 16b-3(e). This means shares were surrendered to the company to cover federal and state tax withholding obligations arising from the vesting of restricted stock units, rather than being sold in the open market. Following this transaction, the CFO beneficially owned 437,931 shares of Class A common stock directly.
An officer of Hinge Health, Inc. reported selling 15,000 shares of the company’s Class A common stock on 12/22/2025. The shares were sold in an open-market transaction at a weighted average price of $48.3967, with individual sale prices ranging from $47.785 to $48.74.
The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025, which is designed to allow insiders to trade on a scheduled basis. After this transaction, the reporting person beneficially owns 769,778 shares of Hinge Health’s Class A common stock. The total in Table I also reflects a correction to the reported ownership previously shown in Forms 4 filed on November 24, 2025 and December 1, 2025.
Hinge Health, Inc. Chief Financial Officer James Budge reported selling 10,491 shares of Class A common stock on 12/22/2025 in an open-market transaction. The shares were sold at a weighted average price of $48.4069 per share, with individual sale prices ranging from $47.81 to $48.74. The transaction was executed under a Rule 10b5-1 trading plan that he adopted on June 12, 2025. Following this sale, Budge beneficially owns 441,174 shares of Hinge Health Class A common stock, held directly.